Clinical trial
Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.
NCT06837129 is registered in ClinicalTrials.gov with Thammasat University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.
- Lead sponsor
- Thammasat University
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- November 15, 2023
- Completion date
- February 20, 2025
- Enrollment
- 180 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
caesarean section, intrathecal morphine, neuraxial opioid, postoperative nausea and vomiting